Spider Vein Treatment at a Med Spa: Sclerotherapy vs Laser

Spider veins are the smallest vein size our sources name.

The label of Asclera, the sclerosant drug, defines them as varicose veins 1 mm or less in diameter, with reticular veins the next size up at 1 to 3 mm — and that label definition is the most precise one our sources hold.

Which is why "spider vein removal," as the searches call it, comes down to two procedures.

The first is sclerotherapy.

Asclera (polidocanol; Methapharm; initial US approval 2010) is FDA-approved to sclerose — the label's verb — uncomplicated spider veins (1 mm or less) and uncomplicated reticular veins (1 to 3 mm) in the legs; it has not been studied in veins over 3 mm.

Its label dosing is 0.5% solution for spider veins and 1% for reticular veins, 0.1–0.3 mL per injection, and no more than 10 mL per session.

Two other sclerosant labels matter for context.

Sotradecol (sodium tetradecyl sulfate) is FDA-labeled for small uncomplicated varicose veins of the legs that show simple dilation with competent valves.

Varithena (polidocanol injectable foam; initial US approval 2013) is a different polidocanol product from Asclera, approved for incompetent great saphenous and accessory saphenous veins and visible varicosities of the GSV system — medical varicose-vein disease, not cosmetic spider veins.

The second is laser spider vein treatment, which works from outside the skin.

Lasers are medical devices, so their status is FDA-cleared, not approved: Cutera lists cleared indications for its 1064 nm Laser Genesis treatment that include benign vascular lesions — rosacea, telangiectasias, leg veins and spider veins — alongside wrinkles, red hypertrophic scars, hair reduction, warts and mild-to-moderate inflammatory acne.

The American Academy of Dermatology (AAD) describes laser leg-vein treatment as its own method, separate from sclerotherapy, and this page keeps that distinction too.

The short version of how it works: sclerotherapy puts a sclerosing solution into the vein; laser treatment aims light energy at the vessel from the skin's surface.

Which method fits a given set of veins is the comparison further down — and, ultimately, a licensed provider's call after an examination.

The labels draw the first candidacy line by vein size and location.

Asclera is approved for uncomplicated spider veins (1 mm or less) and reticular veins (1 to 3 mm) in the legs, and it has not been studied in veins over 3 mm.

Sotradecol is labeled for small uncomplicated varicose veins with competent valves.

Veins outside those descriptions are outside what these labels cover.

The label contraindications draw the second.

Asclera is contraindicated with a known allergy to polidocanol and with acute thromboembolic disease.

Sotradecol's label lists more: valvular or deep vein incompetence, acute thrombophlebitis, bedridden patients and asthma are among its named contraindications.

Then there is the question underneath the cosmetic one: whether the veins are a symptom of vein disease.

NHLBI, the National Heart, Lung, and Blood Institute, explains that varicose veins result from weak or damaged vein walls and valves causing reflux, and that they are commonly diagnosed with duplex ultrasound.

On what the drug labels do not settle — breastfeeding, medicines, other conditions — our sources hold no candidacy answers for the sclerosants, so we will not invent them; for laser, the only contraindication list in our sources is Cutera's for its 1064 nm Laser Genesis treatment (pregnancy, active skin-cancer treatment), reported in the risks section below.

What is left is a licensed provider's judgment, made with your history in front of them.

Start with what we cannot tell you: we found no current national average price for sclerotherapy.

ASPS's 2025 procedural statistics release does not report counts or fees for minimally invasive procedures, which leaves no current ASPS average fee for sclerotherapy, and our research found no other national figure we could stand behind.

A price you see online is that practice's or chain's own number, not a benchmark.

What the sources do support is the shape of the price.

For sclerotherapy, the AAD says 2–3 treatments may be needed, and Asclera's label spaces repeat sessions 1 to 2 weeks apart.

For laser leg-vein treatment, the AAD says complete clearing may need 3 or more treatments.

The number of sessions is a main price driver, so the quote that matters is for the course a practice recommends, not for one visit.

Since there is no verified national figure to compare against, the workable numbers are itemized quotes.

When you collect them, ask what each one includes: the price of a single session versus a package for the full course, whether compression stockings are included or bought separately, and what a follow-up or touch-up session costs.

Ask for the session count in writing before you pay.

For sclerotherapy, the AAD's timeline: spider veins usually disappear in 3 to 6 weeks, while varicose veins take 3 to 4 months, and 2–3 treatments may be needed.

Asclera's label spaces repeat sessions 1 to 2 weeks apart.

For laser, the AAD's description of leg-vein treatment: small spider veins may vanish immediately, while larger ones darken and remain visible for 1 to 3 months.

To get complete clearing, the AAD says you may need 3 or more treatments.

On how long results hold, our sources give one honest line: NHLBI notes that new varicose veins may form even after treatment and that treatments may need repeating.

That finding is about varicose-vein treatment specifically, and no recurrence figure for cosmetic spider veins appears in our sources — so we won't invent one.

Two compression timelines keep their sources separate.

Asclera's label requires compression for 2 to 3 days after spider-vein treatment and 5 to 7 days for reticular veins; the AAD's description of sclerotherapy has most patients wearing compression stockings for 2 to 3 weeks.

The label is the drug's minimum instruction, the AAD is describing practice, and the practice you visit should tell you which plan applies to you and why.

The best-sourced pain numbers are Asclera's.

In its pivotal EASI study — 180 people given Asclera — injection-site pain was reported by 24%, against 9% on placebo.

Hematoma (bruising) was the most common injection-site reaction at 42% versus 19% on placebo, followed by irritation 41% versus 30%, discoloration 38% versus 4%, pain 24% versus 9%, itching 19% versus 4% and warmth 16% versus 6%.

The AAD also notes that no anesthesia is required for sclerotherapy.

For laser leg veins, our sources give no pain rate.

A 2012 split-leg study found a significant difference in pain between 1064 nm Nd:YAG laser and sclerotherapy, in 30 women; our sources record that the difference was significant but not which method was more painful, so comfort during either procedure is a direct question for each practice.

Downtime is mostly compression and sun discipline.

The Asclera label requires a 15–20 minute walk under observation after treatment, to watch for allergic reaction, plus compression stockings for 2 to 3 days for spider veins or 5 to 7 days for reticular veins, to reduce the risk of deep vein thrombosis.

After laser leg-vein treatment, the AAD says the area needs sun protection for 3 to 4 weeks, and larger treated veins darken and remain visible for 1 to 3 months.

The Asclera label carries the serious warnings, and they are worth reading in full.

It warns of severe allergic reactions following polidocanol use, including anaphylactic reactions, some of them fatal, and says they are more frequent with volumes over 3 mL.

It warns that intra-arterial injection or extravasation — leakage outside the vein — can cause severe necrosis, ischemia or gangrene.

And it contraindicates the drug with known polidocanol allergy and acute thromboembolic disease.

Sotradecol's label reports at least six deaths, including four from anaphylactic shock, and carries a long contraindication list of its own.

These labels describe the sclerosant drugs a sclerotherapy session injects; the reactions Asclera's study measured most often, though, were the local ones in the pain section above, and Asclera's postmarketing reports include skin hyperpigmentation and injection-site necrosis.

NHLBI adds the foam-sclerotherapy picture: foam sclerotherapy can rarely cause venous thromboembolism, nerve damage, serious allergic reaction or stroke.

NHLBI gives that line on its varicose-vein page, and it belongs in the picture.

For laser, Cutera's safety information for its 1064 nm treatment lists possible adverse events including redness, swelling, purpura, hyper- and hypopigmentation, burns, blistering and scarring; it lists pregnancy and active skin-cancer treatment as contraindications, and says tanned skin should not be treated.

The honest summary of the head-to-head evidence is two small studies with differing results.

In a 2002 randomized split-leg study (n=20), leg telangiectasias responded better and in fewer sessions to sclerotherapy with sodium tetradecyl sulfate than to a long-pulsed 1064 nm Nd:YAG laser; the authors wrote that laser is most useful for telangiectatic matting, needle phobia or sclerosant allergy.

In a 2012 randomized split-leg study of 30 women, the two methods treated leg telangiectasias equally well after three sessions — with 75% glucose as the sclerosant — though with a significant difference in pain between methods.

Both studies are small, they disagree, and they used different sclerosants, so we will not declare a winner, and neither should a practice's marketing.

We also did not find a study that sorts the two methods by vein size beyond the size ranges in the Asclera label.

What the labels do sort is vein type: Asclera for the smallest vessels, Sotradecol for small uncomplicated varicose veins with competent valves, and Varithena for great-saphenous-vein disease — a medical treatment, not a cosmetic one.

If your concern is varicose veins rather than the small, uncomplicated veins these labels cover, the varicose-vein treatments are the relevant category, evaluated with duplex ultrasound per NHLBI's description.

Which method fits which veins is a licensed provider's call, made after examining them.

The question to take into a consultation is which one the practice would choose for your veins, and why.

Two things decide how a spider vein treatment goes: who performs it, and how the practice prices it.

Both are checkable before you pay anything.

On who performs it: our research did not find a federal rule that sets who may perform cosmetic sclerotherapy, and the question is treated as a state-law matter.

Which licenses and supervision each state requires for injections is its own subject — our med spa laws by state guide covers the rules our research verified.

At the practice, the direct questions are who will perform the procedure, what license that person holds, and how much of this work they do.

On the medical side, the consultation should settle candidacy for the specific method: whether the veins fit Asclera's label sizes (spider veins 1 mm or less, reticular veins 1 to 3 mm), whether anything on the contraindication lists applies to you — polidocanol allergy and acute thromboembolic disease for Asclera — and how the practice evaluates the veins first, given that duplex ultrasound is how varicose veins are commonly diagnosed per NHLBI.

Questions worth asking before you book:

For the full vetting process — credentials, consultations, pricing red flags and ownership — our how to choose a med spa checklist goes deeper.

Take the same questions to every practice you find when you search spider vein treatment near you: the answers, plus an itemized quote, are the most concrete data you will have before booking anything.